Company Overview and News

10
AIM2 Ventures Inc. Announces Upsize to Previously Announced Canopy Rivers’ Private Placement Offering of Subscription Receipts

2h globenewswire
TORONTO, June 18, 2018 (GLOBE NEWSWIRE) -- AIM2 Ventures Inc. (TSXV:AIMB.P) (“AIM2”) is pleased to announce that Canopy Rivers Corporation (“Canopy Rivers”) has amended the terms of its previously announced best efforts private placement (the “Offering”) of subscription receipts (the “Subscription Receipts”). Pursuant to the revised terms of the Offering, Canopy Rivers proposes to issue and sell Subscription Receipts at a price of $3.
TWMJF WEED CGC

14
Canadian Cannabis Overproduction And Its Gold Rush Alternatives

2018-06-16 seekingalpha
Projections of Canadian market demand based on Colorado data put demand estimates at 669,000kg of dried cannabis annually.
TWMJF WEED APHQF CNTTF MEDFF CGC HYYDF

37
CANADA STOCKS - TSX dips 0.14 percent after U.S. Fed rate hike

2018-06-13 reuters
NEW YORK, June 13 (Reuters) - * The Toronto Stock Exchange’s S&P/TSX fell 23.16 points, or 0.14 percent, to 16,265.82. * The biggest weight to the TSX loss was Suncor Energy with a drag of 5.35 index points. In turn, energy weighed by 18.7 points on the index. * Leading the index were Aecon Group Inc, up 3.7 percent, NovaGold Resources Inc, up 3.7 percent, and Precision Drilling Corp , higher by 3.
IFSPF ACBFF IVN NG PDS CGC SU AEGXF IVPAF TWMJF ACB WEED BDRPF ARE PFSCF SU

40
CANADA STOCKS-TSX edges lower as energy shares drag

2018-06-12 reuters
June 12 (Reuters) - Canada’s main stock index edged lower on Tuesday as energy shares fell after OPEC cited a high degree of uncertainty regarding the global oil market this year.
TAHO TWMJF ACB THO WEED ACBFF PBA CGC SU SU

18
Plays On Picks And Shovels In The Cannabis Industry

2018-06-12 seekingalpha
Because of the company’s role as a tester, EVIO is expected to benefit from regulatory overhang unlike other companies in the industry.
TWMJF ACB EVIO ACBFF WEED CGC

16
Weekly Cannabis Report: Legalization Is Here, What's Next?

2018-06-11 seekingalpha
Welcome to our Weekly Cannabis Report, a reliable source for cannabis investors to receive the latest developments and analysis.
TWMJF HMLSF WEED APHQF CGC

18
CANADA STOCKS - TSX edges up 0.06 percent

2018-06-08 reuters
SAN FRANCISCO, June 8 (Reuters) - * The Toronto Stock Exchange’s S&P/TSX rose 9.91 points, or 0.06 percent, to 16,202.69. * The biggest contributor to the TSX gain was Royal Bank of Canada, up 0.49 percent, while financials was the top sector contributor, up 0.2 percent. * Leading the index were Enghouse Systems Ltd, up 8.1 percent, Transcontinental Inc, up 5.3 percent, and Dollarama Inc , higher by 3.
EGHSF BIR BIREF NUVSF ACBFF TCLAF TCLCF CGC TOLWF NVA TWMJF ACB ESL WEED PFSCF

33
Brewers see future in high tech, weak beer, cannabis brews

2018-06-08 reuters
BRUSSELS, June 8 (Reuters) - A ‘smart’ bottle opener, weak and alcohol-free ales and lagers and cannabis brews - all visions of the future of beer offered at a brewing convention in Brussels this week.
STZ.B TWMJF BUD WEED AHBIF STZ CGC

17
Toronto stock index down as shares of cannabis producers decline

2018-06-08 thestar
This copy is for your personal non-commercial use only. To order presentation-ready copies of Toronto Star content for distribution to colleagues, clients or customers, or inquire about permissions/licensing, please go to: www.TorontoStarReprints.com
TWMJF APH WEED APHQF CGC

29
CANADA STOCKS-TSX lower as financials, energy stocks weigh

2018-06-08 reuters
June 8 (Reuters) - Canada’s main stock index slipped on Friday, weighed down by financial stocks and the energy sector, as the specter of a trade war loomed ahead of a Group of Seven summit in Quebec.
RY TNTTF ACBFF RY.PRSCL RBCDF CGC TD TWMJF ACB RY APH WEED RY.PRS APHQF RY.PRT TD

11
Trudeau Legal Weed Plan Remains on Track as Senate Passes Bill - Bloomberg

2018-06-08 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
TWMJF WEED CGC

19
Legalization Of Marijuana In Canada And The True Potential Of Canopy Growth

2018-06-08 seekingalpha
CGC is touted as a top play on the legalization of recreational cannabis but there’s one potential problem.
STZ.B TWMJF WEED STZ CGC

24
Canada clears major hurdle in legalizing recreational marijuana

2018-06-08 cnbc
Canada's Senate on Thursday voted to legalize recreational marijuana, clearing a major hurdle that puts the country on track to become the first Group of Seven nation to permit national use of the drug.
TWMJF ACB APH WEED ACBFF APHQF CGC

23
May Dividend Income Report

2018-06-08 seekingalpha
In September 2017, I received slightly over $100K as a result of the commuted value of my pension plan. I decided to invest 100% of this money into dividend growth stocks. Each month I publish my results. I don't do this to brag, I do this to show you it's possible to build a portfolio during an all-time high market. The market will crash… eventually. In the meantime, I rather cash out on some juicy dividends!
VIG ANCUF ANCTF ENB FTS CGC ENB TWMJF V ATD.A ATD.B FTS WEED

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

10h - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...

Silicon Investor Message Boards

This table lists all message boards related to TSXV:WEED / Canopy Growth Corporation on message board site Silicon Investor.

Stoners Hideout POT-Weed-MJ-Cannabus- Stocks
New World Brands - New Weed Brands = NWBD Tumbleweed Communications Corp. (TMWD)
WF5L Weed and Soil Studies
CUSIP: 901164